One Office Visit, Multiple Vaccines: When is it OK?

Respiratory Tripledemic 2022-23: An Expert Recap

Your daily dose of the clinical news you may have missed.

April 6th 2023

Shingrix Nearly 80% Effective Against Shingles in Older Adults up to 11 Years Post-Vaccination

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

April 18th 2024

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

Vaccine efficacy remained high at 82% at year 11 following vaccination, according to new long-term data.

May 20th 2022

Tezepelumab for COPD Moves into Phase 3 Planning

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

GSK Announces FDA PDUFA Date for 5-in-1 Meningococcal Vaccine Based on Acceptance of BLA

Tezepelumab, a TSLP inhibitor, reduced COPD exacerbations in individuals with moderate/very severe COPD, regardless of baseline BEC and inflammatory drivers, Amgen said.

GSK Announces FDA PDUFA Date for 5-in-1 Meningococcal Vaccine / image credit GSK vaccines: ©desertsands/stock.adobe.com

FDA Approves Benralizumab as Add-On Maintenance Therapy for Children with Severe Asthma: Daily Dose

The FDA expects to take action on the GSK BLA for its pentavalent MenB vaccine by February 14, 2025.

Related Content

April 19th 2024

Respiratory Tripledemic 2022-23: An Expert Recap

Your daily dose of the clinical news you may have missed.

April 6th 2023

Shingrix Nearly 80% Effective Against Shingles in Older Adults up to 11 Years Post-Vaccination

William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.

April 18th 2024

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

Vaccine efficacy remained high at 82% at year 11 following vaccination, according to new long-term data.

May 20th 2022

Tezepelumab for COPD Moves into Phase 3 Planning

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

GSK Announces FDA PDUFA Date for 5-in-1 Meningococcal Vaccine Based on Acceptance of BLA

Tezepelumab, a TSLP inhibitor, reduced COPD exacerbations in individuals with moderate/very severe COPD, regardless of baseline BEC and inflammatory drivers, Amgen said.